Expression of Cell Cycle Regulator P57kip2, CyclinE Protein and Proliferating Cell Nuclear Antigen in Human Pancreatic Cancer: an Immunohistochemical Study

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2005 Aug 27

PMID 16124066

Citations 11

Authors

Hui Yue

Hui-Yong Jiang

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate the effects of p57(kip2), cyclinE protein and proliferating cell nuclear antigen (PCNA) on occurrence and progression of human pancreatic cancer.

Methods: The expression of p57(kip2), cyclinE protein and PCNA in tumor tissues and adjacent tissues from 32 patients with pancreatic cancer was detected by SP immunohistochemical technique.

Results: The positive expression rate of p57(kip2) protein in tumor tissues was 46.9%, which was lower than that in adjacent pancreatic tissues (chi(2) = 5.317, P<0.05). p57(kip2) protein positive expression remarkably correlated with tumor cell differentiation (P<0.05), but not with lymph node metastasis (P>0.05). The positive expression rate of cyclinE protein in tumor tissues was 68.8%, which was higher than that in adjacent pancreatic tissues (chi(2) = 4.063, P<0.05). CyclinE protein positive expression significantly correlated with tumor cell differentiation and lymph node metastasis (P<0.05). The positive expression rate of PCNA in the tumor tissues was 71.9%, which was higher than that in adjacent pancreatic tissues (chi(2) = 5.189, P<0.05). PCNA positive expression remarkably correlated with tumor cell differentiation and lymph node metastasis (P<0.05).

Conclusion: The decreased expression of p57(kip2) and/or overexpression of cyclinE protein and PCNA may contribute to the occurrence and progression of pancreatic cancer. p57(kip2), cyclinE protein, and PCNA play an important role in occurrence and progression of pancreatic cancer.

Citing Articles

Cyclins and cyclin-dependent kinases: from biology to tumorigenesis and therapeutic opportunities.

Zabihi M, Lotfi R, Yousefi A, Bashash D J Cancer Res Clin Oncol. 2022; 149(4):1585-1606.

PMID: 35781526 DOI: 10.1007/s00432-022-04135-6.

Semaphorin7A Promotion of Tumoral Growth and Metastasis in Human Oral Cancer by Regulation of G1 Cell Cycle and Matrix Metalloproteases: Possible Contribution to Tumoral Angiogenesis.

Saito T, Kasamatsu A, Ogawara K, Miyamoto I, Saito K, Iyoda M PLoS One. 2015; 10(9):e0137923.

PMID: 26378920 PMC: 4574527. DOI: 10.1371/journal.pone.0137923.

RNA interference of Biot2 induces G1 phase arrest and apoptosis in mouse colorectal cancer cell line.

Zhou C, Zhang P, Xu G, Wu D, Liu R, Zeng Q Oncol Res. 2015; 22(2):93-103.

PMID: 25706396 PMC: 7838428. DOI: 10.3727/096504014X14146137738583.

Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors.

Peyressatre M, Prevel C, Pellerano M, Morris M Cancers (Basel). 2015; 7(1):179-237.

PMID: 25625291 PMC: 4381256. DOI: 10.3390/cancers7010179.

WWP2 is overexpressed in human oral cancer, determining tumor size and poor prognosis in patients: downregulation of WWP2 inhibits the AKT signaling and tumor growth in mice.

Fukumoto C, Nakashima D, Kasamatsu A, Unozawa M, Shida-Sakazume T, Higo M Oncoscience. 2015; 1(12):807-20.

PMID: 25621296 PMC: 4303889. DOI: 10.18632/oncoscience.101.

References

Czyzewska J, Guzinska-Ustymowicz K, Lebelt A, Zalewski B, Kemona A . Evaluation of proliferating markers Ki-67, PCNA in gastric cancers. Rocz Akad Med Bialymst. 2005; 49 Suppl 1:64-6. View

Kunimoto Y, Nakamura T, Ohno M, Kuroda Y . Relationship between immunohistochemical evaluation of thymidylate synthase and proliferating cell nuclear antigen labeling index in gastrointestinal carcinoma. Oncol Rep. 2004; 12(6):1163-7. View

Lee M, Reynisdottir I, Massague J . Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev. 1995; 9(6):639-49. DOI: 10.1101/gad.9.6.639. View

Orlow I, Iavarone A, Bonilla F, Latres E, Lee M, Gerald W . Cyclin-dependent kinase inhibitor p57KIP2 in soft tissue sarcomas and Wilms'tumors. Cancer Res. 1996; 56(6):1219-21. View

Ito Y, Takeda T, Wakasa K, Tsujimoto M, Matsuura N . Expression of p57/Kip2 protein in pancreatic adenocarcinoma. Pancreas. 2001; 23(3):246-50. DOI: 10.1097/00006676-200110000-00004. View

Ito Y, Takeda T, Sasaki Y, Sakon M, Yamada T, Ishiguro S . Expression of p57/Kip2 protein in extrahepatic bile duct carcinoma and intrahepatic cholangiocellular carcinoma. Liver. 2002; 22(2):145-9. DOI: 10.1034/j.1600-0676.2002.01532.x. View

Rosenberg E, Demopoulos R, Zeleniuch-Jacquotte A, Yee H, Sorich J, Speyer J . Expression of cell cycle regulators p57(KIP2), cyclin D1, and cyclin E in epithelial ovarian tumors and survival. Hum Pathol. 2001; 32(8):808-13. DOI: 10.1053/hupa.2001.26462. View

Keyomarsi K, Tucker S, Buchholz T, Callister M, Ding Y, Hortobagyi G . Cyclin E and survival in patients with breast cancer. N Engl J Med. 2002; 347(20):1566-75. DOI: 10.1056/NEJMoa021153. View

Kondo M, Matsuoka S, Uchida K, Osada H, NAGATAKE M, Takagi K . Selective maternal-allele loss in human lung cancers of the maternally expressed p57KIP2 gene at 11p15.5. Oncogene. 1996; 12(6):1365-8. View

10.

Noura S, Yamamoto H, Sekimoto M, Takemasa I, Miyake Y, Ikenaga M . Expression of second class of KIP protein p57KIP2 in human colorectal carcinoma. Int J Oncol. 2001; 19(1):39-47. DOI: 10.3892/ijo.19.1.39. View

11.

Sato T, Konishi K, Kimura H, Maeda K, Yabushita K, Tsuji M . Evaluation of PCNA, p53, K-ras and LOH in endocrine pancreas tumors. Hepatogastroenterology. 2000; 47(33):875-9. View

12.

Hunter T, Pines J . Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell. 1994; 79(4):573-82. DOI: 10.1016/0092-8674(94)90543-6. View

13.

Sherr C . G1 phase progression: cycling on cue. Cell. 1994; 79(4):551-5. DOI: 10.1016/0092-8674(94)90540-1. View

14.

Ito Y, Yoshida H, Nakano K, Kobayashi K, Yokozawa T, Hirai K . Expression of p57/Kip2 protein in normal and neoplastic thyroid tissues. Int J Mol Med. 2002; 9(4):373-6. View

15.

Ito Y, Takeda T, Sakon M, Tsujimoto M, Monden M, Matsuura N . Expression of p57/Kip2 protein in hepatocellular carcinoma. Oncology. 2001; 61(3):221-5. DOI: 10.1159/000055378. View

16.

Clurman B, Roberts J . Cell cycle and cancer. J Natl Cancer Inst. 1995; 87(20):1499-501. DOI: 10.1093/jnci/87.20.1499. View

17.

Matsuoka S, Edwards M, Bai C, Parker S, Zhang P, Baldini A . p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev. 1995; 9(6):650-62. DOI: 10.1101/gad.9.6.650. View

18.

Grana X, Reddy E . Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene. 1995; 11(2):211-9. View

19.

Matsumoto M, Furihata M, Ohtsuki Y, Sasaguri S, Ogoshi S . Immunohistochemical characterization of p57KIP2 expression in human esophageal squamous cell carcinoma. Anticancer Res. 2000; 20(3B):1947-52. View

20.

OSHITA T, Shigemasa K, Nagai N, Ohama K . p27, cyclin E, and CDK2 expression in normal and cancerous endometrium. Int J Oncol. 2002; 21(4):737-43. DOI: 10.3892/ijo.21.4.737. View